Trevi Therapeutics Q4 EPS $(0.06) Beats $(0.10) Estimate

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 losses of $(0.06) per share, surpassing the analyst consensus estimate of $(0.10) by 41.18%. This represents a 45.45% improvement compared to losses of $(0.11) per share in the same quarter last year.